Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4

Ferroptosis holds great potential as a therapeutic approach for gastric Cancer (GC), a prevalent and deadly malignant tumor associated with high rates of incidence and mortality. Myricetin, well-known for its multifaceted biomedical attributes, particularly its Anticancer properties, has yet to be thoroughly investigated regarding its involvement in Ferroptosis. The aim of this research was to elucidate the impact of myricetin on Ferroptosis in GC progression. The present study observed that myricetin could trigger Ferroptosis in GC cells by enhancing malondialdehyde production and Fe²⁺ accumulation while suppressing glutathione levels. Mechanistically, myricetin directly interacted with NADPH Oxidase 4 (NOX4), influencing its stability by inhibiting its ubiquitin degradation. Moreover, myricetin regulated the inhibition of Ferroptosis induced by Helicobacter pylori cytotoxin-associated gene A (CagA) through the NOX4/NRF2/GPX4 pathway. In vivo experiments demonstrated that myricetin treatment significantly inhibited the growth of subcutaneous tumors in BALB/c nude mice. It was accompanied by increased NOX4 expression in tumor tissue and suppression of the NRF2/GPX4 antioxidant pathway. Therefore, this research underscores myricetin as a novel inducer of Ferroptosis in GC cells through its interaction with NOX4. It is a promising candidate for GC treatment.

NOX4; ferroptosis; gastric cancer; myricetin.